SOPHIA ANTIPOLIS, France – October 25, 2023 │ The quarterly report for the Q3 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on an aspect of mRNA design that that ended up in a Nobel prize! mRNA[…]
SOPHIA ANTIPOLIS, France – August 31, 2023 │The quarterly report for the Q2 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on current dynamics in mRNA design. Exploring the dynamic activity of therapeutic mRNA innovations Therapeutic mRNA,[…]
Monitoring litigations in the therapeutic mRNA field SOPHIA ANTIPOLIS, France – June 06, 2023 │ With the COVID-19 crisis, mRNA technologies have become key for numerous players. After the success of mRNA vaccine and the related hype, players are looking to settle their activity and strengthen their position. With this new phase comes litigations. Moderna[…]
SOPHIA ANTIPOLIS, France – April 21, 2023 │ The quarterly report for the Q1 2023 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Let’s focus on current dynamics in mRNA design & delivery. Q1 2023: Exploring the dynamic activity of[…]